It is important than the many sufferers of age-related macular degeneration (AMD) throughout Europe are given the help they need to try and overcome the condition, and this means new breakthroughs in research, one expert has noted.
Edmund Mickunas, vice-president of regulatory affairs at Advanced Cell Technology (ACT), made the comments after his company announced that it had received approval form the US Food and Drug Administration for its investigational new drug application.
The therapy is to treat dry AMD, the most common form of the condition, and uses retinal pigment epithelial cells derived from human embryonic stem cells.
Mr Mickunas commented: "It is estimated that over ten million Europeans suffer from AMD, representing a vast unmet need and a significant market opportunity."
He added that ACT is "aggressively" seeking approval from the European Medicines Agency to conduct clinical trials across the continent.
A recent study into possible AMD treatments at the Wilmer Eye Institute at Johns Hopkins School of Medicine found that omega-3 fatty acids can help to stop the condition from developing.
by Martin Burns